Intelligent Bio Solutions announces partnership with Bouygues UK

Intelligent Bio Solutions (INBS) announced a partnership with Bouygues UK, a subsidiary of Bouygues Construction, a multi-billion-dollar global construction firm with 35,600 employees, for the deployment of INBS’s fingerprint drug screening technology across its UK operations. “This partnership demonstrates the commercial viability and operational advantages of our fingerprint drug testing technology with a world-class construction organization,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “Bouygues UK’s decision to transition from third-party services to our technology, backed by quantified ROI analysis, validates our value proposition and ability to scale within multinational accounts. We’re proud to support Bouygues UK’s commitment to workplace safety and operational excellence and view the UK deployment as a foundation for potential expansion across its extended operations.”